Lake Ryan David was granted 110,025 shares and covered exercise/tax liability with 37,453 shares, increasing direct ownership by 10% to 801,579 units (SEC Form 4)

$REPH
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $REPH alert in real time by email
SEC FORM 4 SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
  
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Lake Ryan David

(Last) (First) (Middle)
C/O SOCIETAL CDMO, INC.
1 E. UWCHLAN AVE, SUITE 112

(Street)
EXTON PA 19341

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Societal CDMO, Inc. [ SCTL ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Financial Officer
3. Date of Earliest Transaction (Month/Day/Year)
01/24/2024
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 01/24/2024 A 110,025(1) A $0.00 839,032 D
Common Stock 01/24/2024 F 37,453(2) D $0.35 801,579 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. On January 24, 2024, the Compensation Committee of the Board of Directors of the Issuer determined that performance-vesting criteria were met with regard to 110,025 performance-based restricted stock units granted in a prior year, which were converted into 110,025 shares of common stock on a one-for-one basis.
2. Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of the performance-based restricted stock units.
/s/ Ryan D. Lake 01/26/2024
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Get the next $REPH alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$REPH

DatePrice TargetRatingAnalyst
10/12/2021Outperform
William Blair
More analyst ratings

$REPH
Press Releases

Fastest customizable press release news feed in the world

See more
  • Recro Announces Name Change to Societal CDMO to Reflect Corporate Expansion and Transformation

    With Expanded Industry Expertise, Enhanced Service Offerings and Bi-Coastal Operations, Company Now Optimally Positioned to Support Customers' Goal of Delivering Impactful Medicines to Society New Ticker (NASDAQ:SCTL) to Initiate Trading on March 22, 2022 SAN DIEGO and GAINESVILLE, Ga., March 21, 2022 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (("Recro", NASDAQ:REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced that it is changing its name to Societal CDMO, Inc. to reflect the corporate transformation that has taken place primarily as a r

    $REPH
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Recro Reports Fourth Quarter and Year End 2021 Financial Results

    Recorded Q4 Revenue of $22.3 Million; Full Year Revenue of $75.4 Million More than Tripled Customer Base in 2021; Significantly Diversified Clientele Grew Organic New Business by 63% in 2021; Grew by 147% Including IriSys Acquisition Company to Host Conference Call Today at 4:30 p.m. ET SAN DIEGO and GAINESVILLE, Ga., March 01, 2022 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. ("Recro"; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today reported financial results for the fourth quarter and year ended December 31, 2021. "At this time last yea

    $REPH
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Recro Reports Progress Towards Launching Fill/Finish and Lyophilization Capabilities at San Diego Facility

    SAN DIEGO, Calif. and GAINESVILLE, Ga., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (("Recro", NASDAQ:REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today reported key progress in adding fill/finish and lyophilization capabilities to its broad suite of CDMO offerings. All construction and equipment installation related to this service expansion has been completed at the company's San Diego facility and final validation and commissioning activities are underway. The company expects that its new automated fill/finish line and lyophilization

    $REPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

$REPH
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$REPH
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$REPH
SEC Filings

See more

$REPH
Leadership Updates

Live Leadership Updates

See more
  • Recro Announces Executive Changes

    MALVERN, Pa., Dec. 16, 2020 (GLOBE NEWSWIRE) -- Recro (Nasdaq:REPH), a leading contract development and manufacturing organization (CDMO), with integrated solutions for formulation, analytical services, regulatory support, manufacturing and packaging of both commercial and development stage oral solid dose drug products, today announced that David Enloe has been named President, Chief Executive Officer and a member of the Company’s Board of Directors, replacing Gerri Henwood, effective today. Mr. Enloe brings over two decades of executive leadership experience in biotechnology, clinical drug development and GMP manufacturing to Recro, with a proven track record of building and growing CDM

    $REPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

$REPH
Financials

Live finance-specific insights

See more
  • Recro to Report Financial Results for Fourth Quarter and Year-end 2021 on March 1, 2022

    SAN DIEGO and GAINESVILLE, Ga., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (("Recro", NASDAQ:REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced that the company will release financial results for the fourth quarter and year-end 2021 after the market close on Tuesday, March 1, 2022. Recro's management team will host a conference call and audio webcast at 4:30 p.m. ET on Tuesday, March 1, 2022 to discuss the financial results and recent operational highlights. To access the live conference call please dial (844) 243-4691 fr

    $REPH
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Recro Reports Third Quarter 2021 Financial Results

    Acquisition of IriSys, Inc. Significantly Expands Customer Pipeline, Facilities and Capabilities Annual Revenue Guidance Increased to between $74 and $76 million Recorded Q3 2021 Revenues of $18.2 Million and Signed Multiple New Business Agreements Further Expanding Customer Base Company to Host Conference Call Today at 4:30 p.m. ET SAN DIEGO and GAINESVILLE, Ga., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. ("Recro"; NASDAQ: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today reported financial results for the third q

    $REPH
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Recro to Report Financial Results for Third Quarter 2021 on November 9, 2021

    SAN DIEGO, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. ("Recro"; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced that the company will release financial results for the third quarter 2021 after the market close on Tuesday, November 9, 2021. Recro's management team will host a conference call and audio webcast at 4:30 p.m. ET on Tuesday, November 9, 2021 to discuss the financial results and recent operational highlights. To access the live conference call please dial (844) 243-4691 from the U.S. or (225) 283-0379 fro

    $REPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

$REPH
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more